

Cite this: *RSC Adv.*, 2017, 7, 36335

Anti-microbial activity of chrysomycin A produced by *Streptomyces* sp. against *Mycobacterium tuberculosis*†

Balaji Muralikrishnan,^a Vipin Mohan Dan,^{‡a} J. S. Vinodh,^a Vellekkatt Jamsheena,^d Ranjit Ramachandran,^a Sabu Thomas,^b Syed G. Dastager,^e K. Santhosh Kumar,^c Ravi Shankar Lankalapalli^d and Ramakrishnan Ajay Kumar^{*a}

Limited efficacy of the BCG (Bacillus Calmette–Guérin) vaccine against adult tuberculosis and the emergence of resistance to existing anti-tuberculosis drugs compel discovery of novel antibiotics against *Mycobacterium tuberculosis*. Actinomycetes are still an attractive platform for the discovery of new antimicrobials, especially from untapped natural hotspots, despite the belief that they are an exhausted resource after repeated re-discoveries. Herein we report the isolation and identification of chrysomycin A from an actinomycete isolated from a coastal area in Kerala. We show for the first time that it has antimycobacterial activity. It was found to be bactericidal to planktonic and intracellular *M. tuberculosis* with an MIC of 3.125 µg mL⁻¹; it is non-hemolytic and has negligible cytotoxicity. The actinomycete that produces chrysomycin A was found to be a *Streptomyces* sp. through 16S rRNA gene sequencing.

Received 17th May 2017

Accepted 4th July 2017

DOI: 10.1039/c7ra05576e

rsc.li/rsc-advances

Introduction

Tuberculosis (TB), caused by the airborne pathogen *Mycobacterium tuberculosis* (MTB) remains a major global health problem. With 1.4 million deaths in 2015, it is still one of the top ten deadly diseases worldwide.¹ Antibiotics are the mainstay for the treatment of TB as the only vaccine currently available (the BCG) does not prevent the disease in adults.² First-line drugs, namely isoniazid, rifampicin, ethambutol and pyrazinamide, are effective in treating TB. However, long duration of treatment (3–6 months) and noncompliance from patients have resulted in the emergence of drug resistant strains that are difficult to kill, and pose a serious threat to global TB control.^{3,4} Emergence of multi-drug resistant (MDR), extensively drug resistant (XDR) and now totally drug resistant (TDR) strains is on the rise globally.^{5–7} Therefore, the need of the hour is to discover efficient novel molecules that have novel targets in the bacterium.

Actinomycetes have provided us with different classes of antibiotics that play a critical role in treating infectious diseases.⁸ They are the source of more than 45% of all known antibiotics and 90% of usable antibiotics available in the market.^{9,10} This is mainly due to their capacity to produce versatile bioactive secondary metabolites through their resourceful biosynthetic gene clusters.¹¹ We hypothesized that ecological biodiversity hotspots such as coastal areas and tropical forests could harbour new strains of actinomycetes from which novel anti-mycobacterials could be isolated.

In this study, we screened culture filtrates of four hundred actinomycetes isolated from coastal areas and Western Ghats of Kerala, India. Ethyl acetate extract of a *Streptomyces* sp. OA161, was found to inhibit virulent laboratory strain MTB H37Rv. The active principle was purified, subjected to structural characterization and identified as chrysomycin A. This is the first report that chrysomycin A has anti-MTB activity. It was found to be non-cytotoxic to myoblast and epithelial cells and did not lyse red blood cells.

Results and discussion

Screening of culture filtrate extracts for antimicrobial activity

Among four hundred isolates of actinomycetes screened for their antimicrobial activity, ethyl acetate extract of the culture filtrate of the isolate OA161 was found to inhibit the growth of MTB *in vitro* (ESI Data 1†). The antimicrobial activity assay was extended to a panel of seven more microbes and the results revealed that it inhibited growth of Gram-positive bacteria but not of Gram-negative bacteria (Table 1). Based on the results,

^aMycobacterium Research Laboratory, Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala, India. E-mail: rakumar@rgcb.res.in

^bCholera and Biofilm Research Laboratory, Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala, India

^cChemical and Environmental Biology, Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala, India

^dChemical Sciences and Technology Division, National Institute for Interdisciplinary Science and Technology, CSIR, Trivandrum, Kerala, India

^eNCIM Resource Centre, CSIR-National Chemical Laboratory, Pune, India

† Electronic supplementary information (ESI) available: Spectroscopic data and other relevant information for chrysomycin A; extract activity, bioautography and phylogenetic tree supportive data are given here. See DOI: 10.1039/c7ra05576e

‡ These authors contributed equally.



M. smegmatis was used as a surrogate organism to identify the active principle in the extract as the assay using MTB at every step of activity-guided separation was laborious and time-consuming. The ethyl acetate extract was fractionated using thin layer chromatography and subsequent bioautography with *M. smegmatis* revealed an inhibitory zone and the spot was named AMF (antimycobacterial fraction) (ESI Data 2†). Subsequently, the anti-MTB activity of AMF was confirmed by resazurin microtitre assay (REMA).

Identification of the active principle

Separation of AMF using HPLC revealed two prominent peaks with retention times 26.4 minutes (compound 2) and 28.7 minutes (compound 1, ESI Data 3†). While the molecule eluted at 26.4 minutes had negligible activity, the one that eluted at 28.7 minutes had strong anti-MTB activity. The active principle was subjected to structural characterization by extensive NMR analysis which helped in identification of compound 1 as chrysomycin A (Fig. 1) which was further confirmed by comparison of the NMR data with that in the published literature^{12–15} (ESI Data 4–6†). The AMF, yellow solid (18 mg) after separation through HPLC yielded compound 1 (2.5 mg) and compound 2 (9.5 mg), respectively.

Antimycobacterial activity of chrysomycin A

Chrysomycin A was tested for antimycobacterial activity against MTB by REMA. Planktonic MTB was inhibited by the molecule at an MIC of 3.125 $\mu\text{g mL}^{-1}$ and the same MIC was observed with commercially available chrysomycin A (Abcam). The MIC we observed is therefore better than that of two first-line anti-TB drugs, ethambutol (4 $\mu\text{g mL}^{-1}$) and pyrazinamide (16 $\mu\text{g mL}^{-1}$).^{16,17}

Time-course experiment with free-living MTB revealed that the activity is bactericidal in nature as the CFUs were reduced by three log₁₀ folds at MIC and more at higher concentrations. In fact, no colonies were found when bacteria were treated with chrysomycin A (3.125 $\mu\text{g mL}^{-1}$) for 24 hours. At this concentration the bactericidal activity was comparable to that of rifampicin (1 $\mu\text{g mL}^{-1}$). Above 7.8 $\mu\text{g mL}^{-1}$, which is the IC₅₀ for THP-1-derived macrophages, no colonies were found at any




Fig. 1 Structure of chrysomycin A.




Fig. 2 Kinetics of bactericidal activity of chrysomycin A on planktonic MTB. Data presented is mean \pm SD of three independent experiments.

time point checked on planktonic MTB (Fig. 2). Interestingly the compound was also found to be inhibitory to intracellular MTB at the same concentration (Fig. 3). The antimycobacterial activity of chrysomycin A is comparable to that of rifampicin (1 $\mu\text{g mL}^{-1}$) as the CFU data suggested. This is the first report that chrysomycin A has anti-MTB activity against planktonic as well as intracellular MTB.

Chrysomycin A was found to inhibit *M. smegmatis* and *B. subtilis* but not Gram negative bacteria by Strelitz *et al.*¹⁴ Our study also showed that it has the ability to inhibit *M. smegmatis* at almost the same concentration (0.6 $\mu\text{g mL}^{-1}$). In addition, it is inhibitory to drug resistant strains of *Staphylococcus aureus*

Table 1 Antimicrobial activity of ethyl acetate extract and chrysomycin A by REMA. Data presented is mean \pm SD of three independent experiments. MIC with no \pm SD represents consistent results with the same value^a

Bacteria tested	Antimicrobial activity of the ethyl acetate extract	MIC ($\mu\text{g mL}^{-1}$) of chrysomycin A
<i>Mycobacterium tuberculosis</i> H37Rv	+	3.125 \pm 0.5
<i>Mycobacterium smegmatis</i> MC ² 155	+	1 \pm 0.2
<i>Staphylococcus aureus</i> ATCC 25923	+	0.5
MRSA (methicillin resistant <i>Staphylococcus aureus</i>)	+	2
VRE (vancomycin resistant <i>Enterococcus faecalis</i>)	+	0.5
<i>Escherichia coli</i> ATCC 25922	–	>25
<i>Pseudomonas aeruginosa</i> ATCC 27853	–	>50
<i>Vibrio cholerae</i> N16961	–	>50

^a “+” denotes antimicrobial activity, “–” no activity.






Fig. 3 Survival of intracellular MTB in the presence of chrysomycin A. Data represented is mean \pm SD of three independent experiments.

and *Enterococcus faecalis*. It was active against MRSA (methicillin resistant *Staphylococcus aureus*) and VRE (vancomycin resistant *Enterococcus faecalis*) *in vitro* with an MIC of $2 \mu\text{g mL}^{-1}$ and $0.5 \mu\text{g mL}^{-1}$, respectively. It was not inhibitory to Gram negative bacteria tested (*E. coli*, *Pseudomonas aeruginosa* and *Vibrio cholerae*). Interestingly, this molecule has also been reported to cause DNA damage and apoptosis in leukemic cell line HL60.¹³ Our study therefore highlights the need for repurposing existing and abandoned drugs as recommended by Boguski *et al.*¹⁸

Chrysomycin A is non-hemolytic

Human erythrocytes were unharmed even at a concentration ten times the MIC against MTB whereas 1% SDS resulted in complete lysis (Fig. 4). This is another attractive characteristic of an ideal antimicrobial lead molecule. MTT assay revealed that cell lines L6 and SW480 were also unaffected even at $31.25 \mu\text{g mL}^{-1}$ while THP-1-derived macrophages had an IC_{50} of $7.8 \mu\text{g mL}^{-1}$, but largely remained unharmed at the MIC ($3.125 \mu\text{g mL}^{-1}$) (Fig. 5).

The high cytotoxicity of chrysomycin A on THP-1 cells in comparison with the others was rather puzzling, however we presume that this is perhaps due to the fact that THP-1 cells are derived from human leukemia, and chrysomycin A has been reported to possess anti-leukemic activity.¹³ Interestingly, when tested on mice, chrysomycin A was not lethal even at 400 mg kg^{-1} dose and it was, on the other hand, found to increase the life span of the tumour-induced animals.¹⁵




Fig. 4 Hemolysis assay: chrysomycin A is non-hemolytic even at ten times the MIC ($31.25 \mu\text{g mL}^{-1}$). Data presented is mean \pm SD of three independent experiments.




Fig. 5 MTT assay: cytotoxicity of chrysomycin A was analyzed on cell lines up to ten times the MIC ($31.25 \mu\text{g mL}^{-1}$). Little or negligible toxicity was found against L6 (rat myoblast cell line) and SW480 (epithelial cell line from colon). It was relatively more toxic against THP-1-derived macrophages. Data presented is mean \pm SD of three independent experiments.

Isolate that produces chrysomycin A is a *Streptomyces* sp. OA161

The partial 16S rRNA gene sequence of our isolate was submitted to GenBank, NCBI (accession number, KX364040). It is 1410 bp in length and 99.07% similar to that of *Streptomyces smyrnaeus*. A phylogenetic tree was generated using neighbor joining method¹⁹ using MEGA 7 software and the isolate forms a separate clade that is characteristic of a separate species (ESI Data 7[†]).

Experimental

General procedures, strains, cell lines and chemicals

Mycobacterium tuberculosis H37Rv was grown in Middlebrook 7H9 medium (Difco) supplemented with 10% OADC (Difco). Other bacteria used in this study are *Mycobacterium smegmatis* mc² 155, *Staphylococcus aureus* ATCC 25953, MRSA (methicillin resistant *Staphylococcus aureus*) clinical strain C10, VRE (vancomycin resistant *Enterococcus faecalis*) clinical strain E8, *E. coli* ATCC 25922, *Pseudomonas aeruginosa* clinical strain R8 and *Vibrio cholera* N16961 and were grown in Luria Bertani broth (HiMedia, Mumbai). The clinical strains were a kind gift from the Department of Microbiology, Government Medical College, Trivandrum. Nalidixic acid, nystatin, gentamycin, phorbol 12-myristate 13-acetate (PMA) and resazurin were purchased from Sigma; Cell lines L6 (rat myoblast), SW480 (epithelial cell from colon) and THP-1 (Human monocytes) were obtained from National Centre for Cell Science, Pune, India. Cell lines were maintained in RPMI1640 (Sigma) or DMEM (Dulbecco's Modified Eagle's Medium, Gibco) with 10% FBS (Gibco). The extracts and antibiotics were prepared in DMSO and the final concentration of DMSO used in the assays was 2% whenever used for antimicrobial activity.

Isolation of actinomycetes

About 10 grams of soil samples were collected in sterile bags from the sub-soil of different ecological niches and were dried under shade. This was suspended in sterile water (1 gm mL^{-1}), serially diluted and plated on selective solid growth media (starch casein agar/actinomycetes isolation agar/ISP-2/ISP-7) with or without nalidixic acid ($100 \mu\text{g mL}^{-1}$) and nystatin ($50 \mu\text{g mL}^{-1}$) and incubated at $25 \text{ }^\circ\text{C}$ for 2 weeks. Once chalky colonies appeared, they were further purified on ISP-2 agar. The



pure colonies were stored in the form of stabs or as glycerol stocks at 4 °C and –20 °C, respectively.

Purification of anti-mycobacterial principle

Single colony of the actinomycete isolate (OA161) was inoculated in modified ISP-2 medium (50 mL) and grown at 30 °C on a shaker incubator (250 rpm). Two glass marbles were introduced into the medium to prevent clumping of the culture. After 6 days, the culture filtrate was prepared by centrifugation of the culture at 6000 rpm for 15 minutes at room temperature followed by filtration through Whatman 3 filter paper, and passing through 0.2 µm membrane filter. The supernatant was frozen at –80 °C before lyophilization. The lyophilized powder of the culture filtrate was extracted with ethyl acetate, chloroform, acetone and methanol and these extracts were concentrated under vacuum and used in the antimicrobial assay.

Resazurin microtitre assay (REMA)

The assay was carried as described by Martin *et al.*²⁰ Briefly, MTB H37Rv and *M. smegmatis* were grown in Middlebrook 7H9 medium, turbidity of the culture was adjusted to McFarland standard 1 and further diluted 20 times. For other test strains, Luria Bertani broth (HiMedia) was used for growth. One hundred microlitre of the diluted culture was transferred to the wells of a 96 well microtitre plate (Thermo Fisher). The extracts and purified active principle were dissolved in DMSO and added to a final concentrations of 200 µg mL⁻¹ to 0.78 µg mL⁻¹ in a final volume of 200 µL per well. The plates were incubated for 7 days, with negative (no drug) and positive controls (rifampicin and ciprofloxacin at 1 µg mL⁻¹). MIC was determined after the addition of Resazurin (0.25% solution in water) on the 8th day which either remains blue or changes to pink (after 24 hours) based on the viability of the bacteria. Blue indicates that the bacteria are susceptible (inhibition), and pink indicates the bacteria are resistant to killing (viable) by the extract.

Thin layer chromatography and bioautography

Normal phase Silica gel 60 F₂₅₄ aluminum TLC plates (Merck, India) were used to fractionate the ethyl acetate extract of the culture filtrate of the isolate. Hexane : Acetone (1 : 1) was used as the mobile phase. The TLC plate was allowed to develop in a sterile, saturated closed chamber for 35 minutes. The fractionated TLC plate was overlaid with Muller Hinton soft agar containing *S. aureus* or *M. smegmatis*. This was allowed to solidify and incubated for 24 hours (*S. aureus*) or 36 hours (*M. smegmatis*) at 37 °C. The active fraction was named AMF (anti-mycobacterial fraction) and this was subjected to HPLC.

Purification and characterization of the active principle

General procedures. Shimadzu HPLC instrument with C18-phenomenex reverse phase column (250 × 21.2 mm, 5 µm) was used for purification of the extract using acetonitrile (ACN) and water. ¹H and ¹³C NMR spectra were recorded at 500 MHz and 125 MHz on a Bruker DRX 500 NMR instrument (Bruker, Rheinstetten, Germany). Deuterated acetone ((CD₃)₂CO) was

used for recording the NMR spectrum, chemical shifts are given in parts per million (ppm), and coupling constants in Hz. HR-ESI-MS analysis was performed on a Thermo Scientific Exactive mass spectrometer with ions given in *m/z*.

Isolation and identification of the active principle. The AMF (yellow solid) was identified as a mixture of two closely related compounds by TLC and ¹H-NMR. The compound mixture was dissolved in acetonitrile (3 mL) and then subjected to purification by reverse-phase preparative HPLC with a gradient program comprising of mobile phase system: solvent A (water) and solvent B (ACN). The linear gradient started with 35% B at 0 min to 80% B for 30 min, and 100% B up to 35 minutes at a flow rate of 7 mL min⁻¹, monitored at 254 nm. Three major peaks were identified at a retention time of 26.4 minutes, 28.7 minutes, and 30.1 minutes (ESI Fig. 3†). The compound eluted at 28.7 minutes was found to inhibit MTB H37Rv *in vitro* and therefore was subjected to characterization by ¹H, ¹³C, 2D NMR and mass spectrometry.

Colony forming unit (CFU) count assay. McFarland standard 1 of mid-log phase MTB H37Rv culture was diluted 20 times and treated with chrysomycin A at varying concentrations (3.125–31.25 µg mL⁻¹) at 37 °C for 6–48 hours. Rifampicin (1 µg mL⁻¹) served as positive control and 2% DMSO as negative control. All the treated and untreated cultures were diluted further and plated on 7H10 agar containing 0.1% casitone (Difco). The cfus were counted after 3 weeks.

Anti-mycobacterial activity on intracellular MTB. Twenty thousand THP-1 cells were seeded and were induced with PMA (20 ng mL⁻¹) for 18–24 hours to differentiate them into macrophages. These cells were infected with MTB H37Rv at an MOI of 20 : 1. Four hours after infection, the external bacteria (which were not phagocytosed) were treated with gentamycin (45 µg mL⁻¹), and the cells were subsequently treated with chrysomycin A (3.125 µg mL⁻¹, 1.56 µg mL⁻¹ and 0.78 µg mL⁻¹). Macrophages treated with rifampicin (1 µg mL⁻¹) were taken as positive control and untreated macrophages as negative control. These were incubated at 37 °C for 48 hours and lysed with distilled water. The lysate was plated on 7H10 agar containing 0.1% casitone (Difco) and the colonies were counted after 3–4 weeks of incubation at 37 °C.

MTT assay. The assay was carried out as described by van Meerloo *et al.*²¹ Briefly, 10 000 cells were seeded per well in a 96 well plate in triplicates. They were treated with chrysomycin A at different concentrations (1–31.25 µg mL⁻¹) and incubated for 48 hours at 37 °C in the presence of 5% CO₂. Twenty microlitre of MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) dye (5 mg mL⁻¹) was added to each well and after 4 hours, the reaction was terminated by adding 200 µL of isopropanol and this dissolves the formazan crystals. This was read at 540 nm on an ELISA reader (Bio-Rad).

Hemolysis assay. The assay was carried out as described by Evans *et al.*²² with minor modifications. Briefly, 10% (v/v) fresh suspension of human erythrocytes in phosphate buffered saline (PBS, pH 7.2) was incubated with various concentrations of chrysomycin A (2–31.25 µg mL⁻¹) at 37 °C for 1 hour. One percent SDS (w/v) in water served as positive control and PBS served as negative control. The suspensions were centrifuged



(3000 × g) for 5 minutes at room temperature and the supernatant was read at 595 nm to measure the amount of hemoglobin released. Hemolysis was interpreted in percentage after calculating it from three individual experiments.

Sequencing of 16S rRNA and polyketide synthase II alpha subunit genes. Genomic DNA was isolated from the isolate OA161 as described by Lee *et al.*²³ The 16S rRNA gene was amplified with universal primers (ESI Table 2†). Fifty microlitre amplification reaction had 1 μL template DNA (50–200 ng), 10 μL 10× PCR buffer with MgCl₂ (Sigma), 1 μL of forward and reverse primer (20 mM) each, 2 μL dNTP mix (5 mM), 1 U Taq DNA polymerase (Sigma) and 34 μL sterile MilliQ water. The reaction conditions were: initial denaturation at 95 °C for 5 minutes, followed by 30 cycles of denaturation at 95 °C for 30 seconds, annealing at 54 °C for 30 seconds and extension at 72 °C for 45 seconds. A final extension was performed at 72 °C for 7 minutes. For polyketide synthase II alpha subunit gene, the amplification reaction conditions remained the same except that the annealing temperature was 62 °C. The products were electrophoresed on a 1% agarose gel containing ethidium bromide and visualized under UV light. The PCR product was purified using GE Healthcare gel band purification kit and sequenced directly using a Taq BigDye Terminator Cycle Sequencing Kit in ABI automated DNA sequencer (Applied Biosystems). Both genes were sequenced with different forward and reverse sequencing primers to cross check the sequence. The sequences were compared with help of Ez-Taxon and BLAST database, respectively.

Conclusion

Chryso mycin A, isolated from a new species of *Streptomyces*, showed bactericidal activity against planktonic as well as intracellular MTB at an MIC of 3.125 μg mL⁻¹. This is the first report of chryso mycin A possessing anti-MTB activity.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

RAK and ST thank financial support from Open Source Drug Discovery (OSDD), Council of Scientific and Industrial Research (CSIR) (OSDD/HCP0001/12FYP/2012-123/Fin/2412), Government of India. BM thanks Council of Scientific and Industrial Research, Government of India, for research fellowship. VMD was supported by Fast Young Scientist Scheme (SERB:SB/FT/LS-322/2012) of Department of Science and Technology, Government of India. VJS thanks OSDD-CSIR for fellowship. SGD thanks financial support from Council of Scientific and Industrial Research, Government of India.

References

1 W. H. Organization, *Global tuberculosis report 2015*, World Health Organization, 2015.

- 2 L. Brandt, J. F. Cunha, A. W. Olsen, B. Chilima, P. Hirsch, R. Appelberg and P. Andersen, *Infect. Immun.*, 2002, **70**, 672–678.
- 3 I. Gelmanova, S. Keshavjee, V. Golubchikova, V. Berezina, A. K. Strelis, G. V. Yanova, S. Atwood and M. Murray, *Bull. W. H. O.*, 2007, **85**, 703–711.
- 4 J. E. de Steenwinkel, T. Marian, G. J. de Knecht, H. A. Verbrugh, R. E. Aarnoutse, M. J. Boeree, M. A. den Bakker, D. van Soolingen and I. A. Bakker-Woudenberg, *Antimicrob. Agents Chemother.*, 2012, **56**, 4937–4944.
- 5 K. Dheda, T. Gumbo, N. R. Gandhi, M. Murray, G. Theron, Z. Udhwadia, G. B. Migliori and R. Warren, *Lancet Respir. Med.*, 2014, **2**, 321–338.
- 6 N. R. Gandhi, P. Nunn, K. Dheda, H. S. Schaaf, M. Zignol, D. Van Soolingen, P. Jensen and J. Bayona, *Lancet*, 2010, **375**, 1830–1843.
- 7 M. Klopper, R. M. Warren, C. Hayes, N. C. Gey van Pittius, E. M. Streicher, B. Muller, F. A. Sirgel, M. Chabula-Nxiweni, E. Hoosain and G. Coetzee, *Emerging Infect. Dis.*, 2013, **19**(3), 449–455.
- 8 A. Raja and P. Prabakarana, *Am. J. Drug Discovery Dev.*, 2011, **1**, 75–84.
- 9 J. Berdy, *J. Antibiot.*, 2005, **58**, 1–26.
- 10 G. B. Mahajan and L. Balachandran, *Front. Biosci., Elite Ed.*, 2011, **4**, 240–253.
- 11 M. Nett, H. Ikeda and B. S. Moore, *Nat. Prod. Rep.*, 2009, **26**, 1362–1384.
- 12 G. T. Carter, A. A. Fantini, J. C. James, D. B. Borders and R. J. White, *J. Antibiot.*, 1985, **38**, 242–248.
- 13 S. K. Jain, A. S. Pathania, R. Parshad, C. Raina, A. Ali, A. P. Gupta, M. Kushwaha, S. Aravinda, S. Bhushan, S. B. Bharate and R. A. Vishwakarma, *RSC Adv.*, 2013, **3**, 21046–21053.
- 14 F. Strelitz, H. Flon and I. N. Asheshov, *J. Bacteriol.*, 1955, **69**, 280–283.
- 15 U. Weiss, K. Yoshihira, R. Highet, R. J. White and T. T. Wei, *J. Antibiot.*, 1982, **35**, 1194–1201.
- 16 S. G. Franzblau, R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer and R. M. Ferguson, *J. Clin. Microbiol.*, 1998, **36**, 362–366.
- 17 G. Jadaun, C. Agarwal, H. Sharma, Z. Ahmed, P. Upadhyay, J. Faujdar, A. K. Gupta, R. Das, P. Gupta and D. Chauhan, *J. Antimicrob. Chemother.*, 2007, **60**, 152–155.
- 18 M. S. Boguski, K. D. Mandl and V. P. Sukhatme, *Science*, 2009, **324**, 1394–1395.
- 19 N. Saitou and M. Nei, *Mol. Biol. Evol.*, 1987, **4**, 406–425.
- 20 A. Martin, M. Camacho, F. Portaels and J. C. Palomino, *Antimicrob. Agents Chemother.*, 2003, **47**, 3616–3619.
- 21 J. van Meerloo, G. J. Kaspers and J. Cloos, *Cancer cell culture: methods and protocols*, 2011, pp. 237–245.
- 22 B. C. Evans, C. E. Nelson, S. Y. Shann, K. R. Beavers, A. J. Kim, H. Li, H. M. Nelson, T. D. Giorgio and C. L. Duvall, *J. Visualized Exp.*, 2013, e50166.
- 23 Y. Lee, H. Kim, C. Liu and H. Lee, *J. Microbiol. Methods*, 2003, **52**, 245–250.

